Lei Dong

Lei Dong

Auto-generated profile, based on publicly available information

Lei Dong

Peking University First Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Regenerative Therapy
Verified
Journal Article
Open access
LDLei Dong
Lei Dong
XLXiaoyu Li
Xiaoyu Li
WLWenyuan Leng
Wenyuan Leng
ZGZhenke Guo
Zhenke Guo
TCTianyu Cai
Tianyu Cai
JLJian Lin
Jian Lin
ADSCs are a large number of mesenchymal stem cells in Adipose tissue, which can be applied to tissue engineering. ADSCs have the potential of multi-directional differentiation, and can differentiate into bone tissue, cardiac tissue, urothelial cells, skin tissue, etc. Compared with other mesenchymal stem cells, ADSCs have a multitude of promising advantages, such as abundant number, accessibility in cell culture, stable function, and less immune rejection. There are two main methods to use ADSCs for tissue repair and regeneration. One is to implant the “ADSCs-scaffold composite” into the injured site to promote tissue regeneration. The other is cell-free therapy: using ADSC-exos or ADSC-CM alone to release a large number of miRNAs, cytokines and other bioactive substances to promote tissue regeneration. The tissue regeneration potential of ADSCs is regulated by a variety of cytokines, signaling molecules, and external environment. The differentiation of ADSCs into different tissues is also induced by growth factors, ions, hormones, scaffold materials, physical stimulation, and other factors. The specific mechanisms are complex, and most of the signaling pathways need to be further explored. This article reviews and summarizes the mechanism and clinical application of ADSCs in tissue injury repair so far, and puts forward further problems that need to be solved in this field, hoping to provide directions for further research in this field.

4 April 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
LKLinghui Kong
Linghui Kong
XTXiaofeng Tang
Xiaofeng Tang
YKYuanyuan Kang
Yuanyuan Kang
LDLei Dong
Lei Dong
JTJianhua Tong
Jianhua Tong
LZLimin Zhu
Limin Zhu
Background: Adrenal venous sampling (AVS) is recognized as the gold standard for subtyping primary aldosteronism (PA), but its invasive nature and technical challenges limit its availability. A recent study reported that sodium chloride cotransporter (NCC) in urinary extracellular vesicles (uEVs) is a promising marker for assessing the biological activity of aldosterone and can be treated as a potential biomarker of PA. The current study was conducted to verify the hypothesis that the expression of NCC and its phosphorylated form (pNCC) in uEVs are different in various subtypes and genotypes of PA and can be used to select AVS candidates.Methods: A total of 50 patients with PA were enrolled in the study. Urinary extracellular vesicles (uEVs) were isolated from spot urine samples using ultracentrifugation. NCC and pNCC expressions were tested in patients diagnosed with PA who underwent AVS. Sanger sequencing of KCNJ5 was performed on DNA extracted from adrenal adenoma.Results: pNCC (1.89 folds, P<.0001) and NCC (1.82 folds, P=0.0002) was more abundant in the uEVs in the high lateralization index (h-LI, ≥ 4) group than in the low LI (l-LI, < 4) group. Carriers of the somatic KCNJ5 mutations, compared with non-carriers, had more abundant pNCC expression (2.16 folds, P=0.0039). Positive correlation between pNCC abundance and plasma aldosterone level was found in this study (R = 0.1220, P = 0.0129).Conclusions: The expression of pNCC in uEVs in patients with PA with various subtypes and genotypes was different. It can be used as biomarker of AVS for PA subtyping.

1 February 2026 in Digital Health
Verified
Journal Article
Open access
LDLei Dong
Lei Dong
YLYuxi Li
Yuxi Li
GZGuopeng Zhou
Guopeng Zhou
JFJin Fang
Jin Fang
JJJie Jiang
Jie Jiang
JLJianping Li
Jianping Li
Background: The original BAMA randomized trial showed that a mobile app–based self-management digital therapeutics (DTx) intervention improved medication adherence and cardiovascular risk-factor control at 12 months in patients with coronary heart disease (CHD). Whether these early benefits are associated with favorable long-term outcomes—a potential legacy effect—remains uncertain. Methods: The BAMA pilot trial was a parallel-group, open-label, single-center randomized controlled trial in which 300 patients with CHD were assigned 1:1 to regular follow-up with or without DTx. The present study was a 12-month landmark post-trial analysis with follow-up through June 2025, corresponding to up to 8 years after randomization. Participants in the landmark cohort were analyzed according to original randomized assignment. Cox models evaluated all-cause and cardiovascular mortality, with Firth penalized Cox regression as a sparse-event sensitivity analysis. Longitudinal lipid trajectories were assessed using linear mixed-effects models based on actual measurement timing. Results: Among 290 participants who completed the 12-month visit, 289 had ascertainable post-landmark follow-up. During a median post-trial follow-up of 7.1 years, 22 participants died, including 13 from cardiovascular causes. After adjustment for baseline age and sex, original DTx assignment was associated with lower all-cause mortality (hazard ratio [HR], 0.38; 95% CI, 0.15–0.98; P=.045) and cardiovascular mortality (HR, 0.19; 95% CI, 0.04–0.87; P=.032). Firth penalized analyses yielded directionally consistent results. No significant group-by-time interactions were observed for total cholesterol, triglycerides, high-density lipoprotein cholesterol, or low-density lipoprotein cholesterol. Conclusions: Original DTx assignment was associated with lower post-landmark all-cause and cardiovascular mortality despite broadly comparable longitudinal lipid trajectories. These findings may be consistent with a potential legacy effect and warrant confirmation in larger prospective studies.